Arrowhead Pharmaceuticals (ARWR) FY2020 results: revenue $88 million, down 47.9% on the year
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $88 million for fiscal 2020, the year ended 30 September 2020, down 47.9% on the year before. Net income was -$85 million, and diluted earnings per share $-0.84. The figures are the company's own, from the 10-K it filed with the SEC on 23 November 2020.
Revenue
$88 million
-47.9% on the year
FY2013FY2020
Operating margin
-105.9%
36.3% a year earlier
FY2013FY2020
Net income
-$85 million
FY2013FY2020
Diluted EPS
-$0.84
FY2013FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
88.0
169
16.1
-47.9%
Research and development
129
81.0
53.0
+59.0%
Operating income
-93.2
61.2
-55.9
Operating margin
-105.9%
36.3%
-346.5%
Pre-tax income
-84.6
68.1
-54.4
Income tax
0.0
0.2
0.0
-98.9%
Effective tax rate
n/a
0.3%
n/a
Net income
-84.6
68.0
-54.5
Net margin
-96.1%
40.3%
-337.3%
Diluted EPS
-$0.84
$0.69
-$0.65
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
-95.8
173
-47.2
Capital expenditure
12.0
12.0
1.4
-0.4%
Free cash flow
-108
161
-48.6
Free cash flow margin
-122.5%
95.4%
-301.3%
Cash from investing
-241
-47.7
-7.4
Cash from financing
258
66.4
60.0
+288.6%
Depreciation and amortisation
4.2
2.7
3.0
+55.6%
Share-based compensation
43.4
12.4
8.5
+250.1%
Diluted shares, weighted
101m
99m
84m
+2.1%
Shares outstanding at period end
102m
96m
89m
+7.2%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
462
245
95.8
+88.8%
Non-controlling interest
n/a
-0.6
-0.6
Debt
0.0
0.0
2.1
Operating lease liabilities
20.0
n/a
n/a
Other liabilities
40.7
106
14.3
-61.6%
Total liabilities and equity
523
350
112
+49.4%
Fixed assets
30.9
23.2
13.9
+33.0%
Intangible assets
15.4
17.1
18.8
-10.0%
Investments
85.0
n/a
n/a
Securities held for sale or to maturity
n/a
81.1
46.4
Cash and equivalents
144
222
30.1
-35.3%
Receivables
0.8
0.7
0.3
+27.9%
Other assets
247
6.0
2.0
+3,996.1%
Total assets
523
350
112
+49.4%
10-K for the year ended 30 September 2020, filed 23 November 2020: the filing.